identification of a dihydroartemisinin-related prognostic signature and its cont

Identification and verification of eight cancer-associated fibroblasts related genes as a prognostic signature ... Dihydroartemisinin ...

e-century.us·14.4 MB

Dihydroartemisinin (DHA) is the active metabolite of artemisinin, which is an effective, fast-acting, and low- toxicity antimalarial drug [16].

link.springer.com·6.7 MB

Dihydroartemisinin. (DHA), a derivative of artemisinin, exhibits signi cant potential in antitumor applications, but its molecular mechanism in ...

www.researchsquare.com·6.5 MB

This study aims to develop a prognostic model based on fatty acid metabolism to improve the overall prognosis of LUAD. Materials and methods: ...

www.frontiersin.org·6.3 MB

In summary, this study demonstrates that nuclear overexpression of phospho-TCTP is correlated with aggressive G2–G3 tumors and suggests that ...

iris.cnr.it·6.1 MB

Dihydroartemisinin may contribute to pancreatic cancer progression via the regulation of ferroptosis.

www.tmrjournals.com·4.7 MB

Novel Markers, Tests, Trials, and. Biology. Sameek Roychowdhury ... What novel therapies can we offer them? FGFR: New questions. 12. Page ...

secure.ketteringhealth.org·3.8 MB

To identify precisely the ideal gene combination, we used the LASSO algorithm based on the 26 significantly DEGs contained in the ceRNA ...

tcr.amegroups.org·3.8 MB

The active metabolite of artemisinin, dihydroartemisinin (DHA), has also displayed antineoplastic effects on breast, glioma, colon, lung, ...

cdn.clinicaltrials.gov·3.2 MB

Among biologic therapies in clinical development, monoclonal antibodies, bi-/multi-specific antibodies, and antibody drug conjugates (ADCs) are the top 3 ...

www.iqvia.com·3.0 MB

High quality biomarkers can markedly accelerate and enable drug development in areas of unmet need. • Biomarkers can improve trial efficiency and ...

fnih.org·1.2 MB

This prognostic gene signature was also found to predict response to chemotherapy commonly used for treating breast cancer, including CMF, Tamoxifen, Paclitaxel ...

stacks.cdc.gov·917.7 KB

poor-prognosis signature, up-regulated genes were associated with the cell cycle, invasion and metastasis, angiogenesis and signal transduction. AD is ...

adni.loni.usc.edu·866.4 KB

When assessed repeatedly, biomarker measurements may sometimes detect signs of disease or condition worsening, which may indicate deteriorating prognosis or a ...

health.uconn.edu·822.1 KB

For example in breast cancer, a poor prognosis gene expression signature in the primary tumor can accurately predict the risk of subsequent metastases, ...

people.physics.illinois.edu·512.3 KB

Biomarkers hold the potential to reduce the time and cost of drug development by improving the efficiency of the clinical trials required to ...

www.brookings.edu·473.0 KB

We next compared 47 published breast cancer outcome signatures to signatures made of random genes. Twenty-eight of them (60%) were not ...

journals.plos.org·442.8 KB

The 5-year relative survival rate among patients diagnosed with lung cancer is only 15%. The vast majority of lung cancer cases. (approximately 80%) are non– ...

brb.nci.nih.gov·383.4 KB

The Prosigna Breast Cancer Prognostic Gene Signature Assay is indicated in female breast cancer patients who have undergone surgery in conjunction with ...

www.accessdata.fda.gov·300.1 KB

Prognostic biomarkers correlate with the progression of a disease. For example, overexpression of HER2 in breast cancer can indicate poor prognosis. These ...

www.bio-rad.com·288.8 KB